TSO3: conference call and webcast for the 2011 annual financial results

Ticker Symbol: TOS/TSX
Shares Outstanding: 58 785 682

QUEBEC CITY, Feb. 20, 2012 /CNW Telbec/ - TSO₃ Inc. ("TSO₃") (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings using ozone, today announced that it will report the Company's annual financial results ending December 31, 2011, on Wednesday, March 14, 2012. TSO₃ will host a conference call at 10:30 A.M. (EST) the same day.

Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3426 (Toronto area) or the toll-free number 1 800 731-5319. Other interested parties may listen to the live Webcast of the Conference Call accessible via TSO₃'s Website at: www.tso3.com. The Webcast will be archived for 90 days.

About TSO₃

TSO₃, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential.  TSO₃ designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.

For more information about TSO₃, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO₃ relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO₃) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO₃ to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

Source: TSO₃ Inc.

Information:

Caroline Côté
Director - Investor and Business Relations
[phone], Ext. 237
Email: [email protected]